Radiantis Research stands at the forefront of medical innovation, addressing the critical landscape of cancer surgery, which plays a pivotal role in contemporary healthcare. With cancer being a leading cause of morbidity and mortality worldwide, accounting for a staggering the significance of advancements in surgical techniques cannot be overstated.
In the ongoing battle against cancer, surgical interventions remain a cornerstone of treatment. Despite remarkable progress, there exists a pressing need for cutting-edge tools that can empower surgeons, elevating the precision and efficacy of oncological procedures. It's imperative to bridge the gap between the potential of modern surgery and the challenges that persist in achieving consistently high-quality outcomes across diverse medical centers.
About us
Radiantis Research is a dynamic team comprised of medical professionals, researchers, and experienced managers hailing from the pharmaceutical and biomedical sectors. Our roots trace back a decade, originating from pioneering research conducted at the National Institute of Nuclear Physics (INFN).
Founded on the collaborative efforts of medical expertise and scientific inquiry, Radiantis Research has evolved into a visionary force in the realm of oncological surgery. Our multidisciplinary team brings together the insights and skills garnered from years of experience, shaping a collective commitment to excellence.
Currently navigating the pre-seed phase, our project is a testament to the tenacity of a decade-long journey. Rooted in the imminent publication of a pivotal Phase 2 clinical study, Radiantis Research is positioned as a catalyst for transformative advancements in the field. This study not only embodies our dedication to rigorous scientific inquiry but also sets the stage for our pivotal role in reshaping the landscape of intraoperative tools for oncological surgery.
Radiantis Research is not just an organization; it is the culmination of years of expertise and a shared vision, poised to make a lasting impact on the future of cancer care.
Our Technology
Beta Probe 1 is a cutting-edge device designed to detect positrons, particles emitted by cancer-specific radiopharmaceuticals commonly used in routine clinical practice for PET (Positron Emission Tomography) diagnostics. In Phase 2 clinical studies, Beta Probe 1 demonstrated outstanding performance:
High Sensitivity: With an impressive 89.3% sensitivity, the device excels in locating lesions within the body.
High Specificity: Achieving a specificity of 86.4%, Beta Probe 1 accurately identifies and targets cancerous cells during surgical procedures.
The device ensures the safety of intraoperative use with the following key features:
Intra-Chirurgical Safety: Beta Probe 1 is engineered for intra-chirurgical safety, ensuring a secure environment for surgical procedures.
Patient Well-being: The device has demonstrated an absence of side effects for patients, contributing to their overall well-being during and after surgery.
Minimal Radiation Exposure: With a focus on staff safety, Beta Probe 1 minimizes radiation exposure for surgical personnel in the operating room.
Enhanced Surgical Precision: Beta Probe 1 goes beyond detection, contributing to increased surgical radicality by enabling the excision of tumor tissue that may not have been identified as pathological before the operation.
In summary, Beta Probe 1 represents a leap forward in intraoperative technology, offering a combination of sensitivity, specificity, safety, and precision that holds immense promise for the future of oncological surgery.
